• Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial

  NCT04448028

  RecruitingInterventionalPhase 4Updated Apr 24, 2025
• Primary carE PPi dEprescRibing Trial

  NCT05629143

  Active, not recruitingInterventionalPhase 4Updated Jan 31, 2025
• Helicobacter Pylori and Body Iron in Adults

  NCT03146325

  WithdrawnInterventionalPhase 4Updated May 9, 2017
• PPIs and In-Hospital Morbidity in Acute Variceal Bleeding With Chronic Liver Disease

  NCT06861478

  RecruitingInterventionalPhase 2Updated Jun 12, 2026
• Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement

  NCT03990181

  CompletedInterventionalNot ApplicableUpdated May 26, 2021
• The Clinical Significance of Acid Rebound in Functional Dyspepsia

  NCT01373970

  TerminatedInterventionalPhase 4Updated Dec 6, 2013

ClinicalTrials.gov ID

NCT01524757

Lead Sponsor

Maastricht University Medical CenterOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Not Applicable

Enrollment

48Estimated

Last Update Posted

Feb 2, 2012Estimated

Start Date

Mar 2012

Primary Completion Date

Aug 2013Estimated

Completion Date

Aug 2013Estimated

Official Title

Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis

Brief Summary

Hereditary Hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload causing damage of different important organs like heart, liver, pancreas and joints. Complications and symptoms can regress by intensive treatment reducing the iron overload stores.Different genes have been identified playing a role in the pathophysiology of iron overload. A clinically important HFE gene mutation is the C282Y, located on chromosome 6. Phlebotomy is currently the standard therapy which consists of removal of 500 ml whole blood weekly, representing a loss of 250 mg iron. In naive patients between 20 to 100 phlebotomies are required to reduce the serum ferritine levels to 50 μg/L. Thereafter, a lifelong maintenance therapy of 3 to 6 phlebotomies yearly is needed.

For absorption, dietary iron ( 70%) is reduced by gastric acid form the ferric (Fe3+) to the ferrous form (Fe2+). Recently, in an observational open study, Hutchinson et al. found that HH patients treated with proton pump inhibitors (PPI) needed fewer phlebotomies, resulting in a drop of 2.5 (SEM 0.25) to 0.5 (SEM 0.25) liter per year.

Research question: The primary objective is to determine the effectiveness and cost effectiveness of PPI's compared to standard phlebotomy therapy in the prevention of iron overload in HH patients.

Multi-center trial in two hospitals in the South of Limburg (Atrium medical Center, Maastricht university medical center ) and hospital in Belgium (University Hospital Gasthuisberg). The study will be conducted in randomised double blind manner. The follow up will be one year.

Patients are randomized either for the group receiving a PPI or a placebo. Every 2 month the ferritin level is measured and decided if the patient need a phlebotomy (Ferritin >100 µg/L).

• Hemochromatosis

• Pantoprazole

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients with hereditary hemochromatosis (HH), homozygous for C282Y, currently treated with phlebotomy as maintenance therapy for at least 12 months with ≥ 3 phlebotomies per year.
• Ferritin level between 50-100 μg/L at start of the inclusion.
• Age: 18 years- 60 years and weight > 50 kg.

Exclusion Criteria:

• Patients receiving other therapies such as chelating therapy or forced dietary regimen.
• Patients younger than 18 years.
• HH patients with excessive overweight (BMI > 35).
• Patients who are mentally incapacitated.
• Women being pregnant or expecting/ planning to become pregnant during the one year period of the study.
• Patients with a malignancy.
• Patients already on PPI treatment.
• Patients who experienced side effects of PPI's.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Maastricht University Medical CenterOTHER

Collaborators

Annadal stichtingUNKNOWN

c.vandeursen@atriummc.nl+31-45-5279639